Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia

A technology of CCFM1131 and Lactobacillus rhamnosus, applied in the field of microbiology, can solve problems such as undiscovered, and achieve the effects of promoting expression, reducing gout, and lowering serum uric acid levels

Active Publication Date: 2021-03-30
无锡特殊食品与营养健康研究院有限公司
View PDF13 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The excretion of uric acid in the human body is mainly through the excretion of the kidneys and intestines. As a uric acid transporter, ABCG2 plays an important role in the intestinal excretion of uric acid. The expression of intestinal ABCG2 is considered to be a new target for the treatment of hyperuricemia and gout. point, but currently no drugs targeting intestinal ABCG2 have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia
  • Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia
  • Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Screening of Lactobacillus rhamnosus CCFM1131

[0047] (1) Isolation and screening of Lactobacillus

[0048] (1) Take 1g of fresh feces of healthy adults. After gradient dilution, it was applied to LBS medium supplemented with 1% nystatin, and placed in a constant temperature incubator at 37°C for 48 hours.

[0049] (2) After cultivation, according to the color, size, and edge shape of the colony, use an inoculation loop to pick up the colony and streak it for purification.

[0050] (3) The obtained colonies were subjected to Gram staining and catalase analysis.

[0051] (4) Retain Gram-positive bacilli and catalase-negative bacteria.

[0052] (2) Molecular biological identification of Lactobacillus

[0053] (1) Single bacterial genome extraction

[0054] (A) cultivating the lactobacilli screened in step (1) overnight;

[0055] (B) Take 1 mL of the bacterial suspension cultivated overnight in a 1.5 mL centrifuge tube, centrifuge at 10000 r / min for 2 min...

Embodiment 2

[0071] Example 2: Lactobacillus rhamnosus CCFM1131 has good tolerance to simulated gastrointestinal fluid

[0072] The cryopreserved Lactobacillus rhamnosus CCFM1131 was inoculated in MRS medium, cultured at 37° C. for 14 hours, and subcultured in MRS medium for 2 to 3 times.

[0073] Take 3mL of the culture solution of Lactobacillus rhamnosus CCFM1131 and centrifuge at 8000×g for 2min to collect the bacteria, mix it with 3mL pH 3.0 artificial simulated gastric juice (containing 3g / L pepsin, pH=3.0 physiological saline), and incubate in a 37°C incubator Cultivate, take samples at 0h and 2h respectively, use MRS agar medium to pour culture, count the colonies on the plate, determine the number of viable bacteria and calculate their survival rate.

[0074] Take 3 mL of the culture solution of Lactobacillus rhamnosus CCFM1131 and centrifuge at 8000×g for 2 min to collect the cells, add 3 mL of pH8.0 artificial simulated intestinal fluid (physiological saline containing 1 g / L tryp...

Embodiment 3

[0078] Example 3: Lactobacillus rhamnosus CCFM1131 has no toxic side effects on KunMing mice

[0079] Resuspend Lactobacillus rhamnosus CCFM1131 in 100g / L skim milk solution to make a concentration of 4.0×10 9 CFU / mL bacterial suspension. Twelve healthy male KunMing mice with a body weight of about 24-32 g were taken, and after one week of adaptation to the environment, they were divided into CCFM1131 group and control group. The CCFM1131 group was given this concentration of bacterial suspension 0.3mL by intragastric administration once a day, and the control group was intragastrically administered the same volume of 100g / L skim milk solution without Lactobacillus rhamnosus CCFM1131, observed for one week, and recorded death and body weight.

[0080] The results of these tests are listed in Table 2. These results indicate that feeding concentrations of 1×10 9 CFU / Lactobacillus rhamnosus CCFM1131 had no significant impact on mice, no significant change in body weight, and n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CCFM1131 can reduce the serum uric acid level of a hyperuricemia mouse, inhibit the xanthine oxidase (XOD) activity of serum and the liver, and reduce the occurrence of hyperuricemia and gout; the lactobacillus rhamnosus CCFM1131 can be used for down-regulating serum blood sugar, down-regulating serum total triglyceride (TG), down-regulating serum total cholesterol (TC) level and inhibiting serum alkaline phosphatase (ALP) activity; in addition, the lactobacillus rhamnosus CCFM1131 can promote the expression of the ileum uric acid transporter ABCG2. Besides, the lactobacillus rhamnosus CCFM1131 can tolerate gastrointestinaltract environment, can be used for preparing functional microbial inoculants, foods and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

Description

technical field [0001] The invention relates to a strain of Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, belonging to the technical field of microorganisms. Background technique [0002] Hyperuricemia (Hyperuricemia, HUA) refers to a disease in which the level of uric acid in the blood exceeds the normal value. In recent years, with the improvement of living standards, the incidence of hyperuricemia is also increasing. In my country, patients with hyperuricemia account for about 13.3% of the total population. Urate stones caused by long-term hyperuricemia can further induce gout. At the same time, hyperuricemia is considered a risk factor for cardiovascular and cerebrovascular diseases, chronic kidney disease, and atherosclerosis, which seriously endangers human health. Therefore, the treatment of hyperuricemia has attracted great attention. At present, the drugs for the treatment of hyperuricemia mainly include allopurinol (xanthine oxidase inhibitor), be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K35/747A61P19/06A61P3/10A61P3/06A61P3/04A23L33/135C12R1/225
CPCA61K35/747A61P19/06A61P3/10A61P3/06A61P3/04A23L33/135A23V2002/00A23V2400/175A23V2200/30
Inventor 赵建新王刚倪彩新王琳琳翟齐啸陆文伟崔树茂杨波毛丙永唐鑫张秋香于雷雷张灏陈卫
Owner 无锡特殊食品与营养健康研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com